Pharmacokinetics of human red blood cell microparticles prepared using high-pressure extrusion method

Wenche Jy, Ashish K. Rehni, Carlos Bidot, Hever Navarro-Quero, Conner R. Haase, Sebastian Koch, Yeon Ahn, Kunjan R Dave

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Red blood cell microparticles (RMPs) is a high potency hemostatic agent, which may serve as a viable therapeutic approach. They generate thrombin in vitro and effective in arresting bleeding in animal bleeding models. However, prior to ascertaining the clinical efficacy of RMPs, detailed preclinical evaluation is necessary. Therefore, we aimed to characterize RMPs, ascertain their stability, and determine their pharmacokinetics in rats. RMPs were prepared from human RBCs by a high-pressure extrusion method. Pharmacokinetic parameters were computed from groups receiving various RMPs dosing regimens. Volume of distribution, elimination rate constant, and clearance for RMPs were also assessed. Major portion of prepared microparticles were RMPs and a very small portion of particles were from platelets and leukocytes. RMPs were stable when stored at 5 and -20°C for at least 12 months. In vivo half-life was found to vary for each paradigm, but in general, was less than 2 min for most of the paradigms evaluated. Our results demonstrate that RMPs are stable during prolonged storage and have a short half-life. Therefore, the clinical use of RMPs as a hemostatic agent, within a tailored treatment paradigm, may be advantageous in achieving prolonged systemic therapeutic benefit without provoking any thrombotic complications.

Original languageEnglish (US)
Article number599
JournalFrontiers in Pharmacology
Volume9
Issue numberJUN
DOIs
StatePublished - Jun 11 2018

Fingerprint

Pharmacokinetics
Erythrocytes
Pressure
Hemostatics
Half-Life
Hemorrhage
Thrombin
Leukocytes
Blood Platelets
Animal Models
Therapeutics

Keywords

  • Dose response
  • Half-life
  • Hemostasis
  • Particle size
  • Shelf-life
  • Volume of distribution

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pharmacokinetics of human red blood cell microparticles prepared using high-pressure extrusion method. / Jy, Wenche; Rehni, Ashish K.; Bidot, Carlos; Navarro-Quero, Hever; Haase, Conner R.; Koch, Sebastian; Ahn, Yeon; Dave, Kunjan R.

In: Frontiers in Pharmacology, Vol. 9, No. JUN, 599, 11.06.2018.

Research output: Contribution to journalArticle

Jy, Wenche ; Rehni, Ashish K. ; Bidot, Carlos ; Navarro-Quero, Hever ; Haase, Conner R. ; Koch, Sebastian ; Ahn, Yeon ; Dave, Kunjan R. / Pharmacokinetics of human red blood cell microparticles prepared using high-pressure extrusion method. In: Frontiers in Pharmacology. 2018 ; Vol. 9, No. JUN.
@article{040d4cc72ac64247913aced1ebd4b2e6,
title = "Pharmacokinetics of human red blood cell microparticles prepared using high-pressure extrusion method",
abstract = "Red blood cell microparticles (RMPs) is a high potency hemostatic agent, which may serve as a viable therapeutic approach. They generate thrombin in vitro and effective in arresting bleeding in animal bleeding models. However, prior to ascertaining the clinical efficacy of RMPs, detailed preclinical evaluation is necessary. Therefore, we aimed to characterize RMPs, ascertain their stability, and determine their pharmacokinetics in rats. RMPs were prepared from human RBCs by a high-pressure extrusion method. Pharmacokinetic parameters were computed from groups receiving various RMPs dosing regimens. Volume of distribution, elimination rate constant, and clearance for RMPs were also assessed. Major portion of prepared microparticles were RMPs and a very small portion of particles were from platelets and leukocytes. RMPs were stable when stored at 5 and -20°C for at least 12 months. In vivo half-life was found to vary for each paradigm, but in general, was less than 2 min for most of the paradigms evaluated. Our results demonstrate that RMPs are stable during prolonged storage and have a short half-life. Therefore, the clinical use of RMPs as a hemostatic agent, within a tailored treatment paradigm, may be advantageous in achieving prolonged systemic therapeutic benefit without provoking any thrombotic complications.",
keywords = "Dose response, Half-life, Hemostasis, Particle size, Shelf-life, Volume of distribution",
author = "Wenche Jy and Rehni, {Ashish K.} and Carlos Bidot and Hever Navarro-Quero and Haase, {Conner R.} and Sebastian Koch and Yeon Ahn and Dave, {Kunjan R}",
year = "2018",
month = "6",
day = "11",
doi = "10.3389/fphar.2018.00599",
language = "English (US)",
volume = "9",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "JUN",

}

TY - JOUR

T1 - Pharmacokinetics of human red blood cell microparticles prepared using high-pressure extrusion method

AU - Jy, Wenche

AU - Rehni, Ashish K.

AU - Bidot, Carlos

AU - Navarro-Quero, Hever

AU - Haase, Conner R.

AU - Koch, Sebastian

AU - Ahn, Yeon

AU - Dave, Kunjan R

PY - 2018/6/11

Y1 - 2018/6/11

N2 - Red blood cell microparticles (RMPs) is a high potency hemostatic agent, which may serve as a viable therapeutic approach. They generate thrombin in vitro and effective in arresting bleeding in animal bleeding models. However, prior to ascertaining the clinical efficacy of RMPs, detailed preclinical evaluation is necessary. Therefore, we aimed to characterize RMPs, ascertain their stability, and determine their pharmacokinetics in rats. RMPs were prepared from human RBCs by a high-pressure extrusion method. Pharmacokinetic parameters were computed from groups receiving various RMPs dosing regimens. Volume of distribution, elimination rate constant, and clearance for RMPs were also assessed. Major portion of prepared microparticles were RMPs and a very small portion of particles were from platelets and leukocytes. RMPs were stable when stored at 5 and -20°C for at least 12 months. In vivo half-life was found to vary for each paradigm, but in general, was less than 2 min for most of the paradigms evaluated. Our results demonstrate that RMPs are stable during prolonged storage and have a short half-life. Therefore, the clinical use of RMPs as a hemostatic agent, within a tailored treatment paradigm, may be advantageous in achieving prolonged systemic therapeutic benefit without provoking any thrombotic complications.

AB - Red blood cell microparticles (RMPs) is a high potency hemostatic agent, which may serve as a viable therapeutic approach. They generate thrombin in vitro and effective in arresting bleeding in animal bleeding models. However, prior to ascertaining the clinical efficacy of RMPs, detailed preclinical evaluation is necessary. Therefore, we aimed to characterize RMPs, ascertain their stability, and determine their pharmacokinetics in rats. RMPs were prepared from human RBCs by a high-pressure extrusion method. Pharmacokinetic parameters were computed from groups receiving various RMPs dosing regimens. Volume of distribution, elimination rate constant, and clearance for RMPs were also assessed. Major portion of prepared microparticles were RMPs and a very small portion of particles were from platelets and leukocytes. RMPs were stable when stored at 5 and -20°C for at least 12 months. In vivo half-life was found to vary for each paradigm, but in general, was less than 2 min for most of the paradigms evaluated. Our results demonstrate that RMPs are stable during prolonged storage and have a short half-life. Therefore, the clinical use of RMPs as a hemostatic agent, within a tailored treatment paradigm, may be advantageous in achieving prolonged systemic therapeutic benefit without provoking any thrombotic complications.

KW - Dose response

KW - Half-life

KW - Hemostasis

KW - Particle size

KW - Shelf-life

KW - Volume of distribution

UR - http://www.scopus.com/inward/record.url?scp=85048288819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048288819&partnerID=8YFLogxK

U2 - 10.3389/fphar.2018.00599

DO - 10.3389/fphar.2018.00599

M3 - Article

AN - SCOPUS:85048288819

VL - 9

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - JUN

M1 - 599

ER -